Hanmi Pharmaceutical subsidiary HS North America has completed its acquisition of all Aptose Biosciences (APS.TO) common shares it does not already own.
Aptose shareholders will receive C$2.41 in cash per common share, representing a 28% premium over Aptose's 30-day volume weighted average price before the agreement was signed, the oncology company said Tuesday.
Aptose common shares will be delisted from the Toronto Stock Exchange at market close on July 3.